Analyst Reco. bluebird bio, Inc.

Equities

BLUE

US09609G1004

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
1.03 ^USD	0.00%		+0.98%	-25.36%

May. 16	Transcript : Bluebird bio, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 09	Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating	Mar. 27	MT
Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating	Mar. 27	MT
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating	Mar. 26	MT
Wedbush Adjusts bluebird bio's Price Target to $1.68 From $3, Maintains Neutral Rating	Mar. 19	MT
HSBC Adjusts bluebird bio's Price Target to $1.02 From $2.31, Keeps Reduce Rating	Mar. 05	MT
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
Wells Fargo Adjusts Bluebird Bio Price Target to $5 From $8, Maintains Equal Weight Rating	Dec. 15	MT
Baird Adjusts Price Target on bluebird bio to $7 From $10, Maintains Outperform Rating	Dec. 12	MT
BofA Securities Adjusts Price Target on bluebird bio to $12 From $11, Maintains Buy Rating	Dec. 11	MT
Wedbush Lowers bluebird bio's PT to $3 From $5, Says Black Box Warning for Lyfgenia Makes it Difficult to Justify Premium; Maintains Neutral Rating	Dec. 11	MT
Top Stories at Midday: Unemployment Rate Falls; Carrier Global Rises on Honeywell Deal; Tesla's Norway Labor Woes; FDA Approves Casgevy, Lyfgenia; Putin's 2024 Presidential Run	Dec. 08	MT
Morgan Stanley Upgrades Bluebird Bio to Equalweight From Underweight, Boosts Price Target to $7 From $3	Dec. 08	MT
Wedbush Lowers bluebird bio's Price Target to $5 From $7, Maintains Neutral Rating	Nov. 08	MT
Cantor Fitzgerald Initiates Coverage on bluebird bio with Neutral Rating	23-10-17	MT
HSBC Initiates bluebird bio With Buy Rating, Price Target is $4.21	23-09-06	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral on Gene Therapy Potential, Adjusts Price Target to $10 From $6	23-07-19	MT
BofA Securities Upgrades bluebird bio to Buy From Neutral, Adjusts Price Target to $10 From $6	23-07-19	MT
RBC Trims bluebird bio's Price Target to $6 From $8, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Barclays Upgrades bluebird bio to Overweight From Equalweight, Adjusts Price Target to $8 From $7	23-06-01	MT
Wedbush Adjusts bluebird bio Price Target to $7 From $5, Maintains Neutral Rating	23-05-09	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. bluebird bio, Inc.

Equities

BLUE

US09609G1004

Analyst Reco.

Filters